Note: based on a RGCC chemosensitivity analysis I have seen at a German clinic, Hydroxychloroquine has been effective in killing the cancer cells of 5 out 7 patients that were tested. It is one of very few available drugs that inhibits autophagy, a mechanism associated with its anticancer properties. Chloroquine and hydroxychloroquine in cancer therapy Chloroquine spc Chloroquine is a potent blocker of autophagy and has been demonstrated in a lab setting to dramatically enhance tumor response to radiotherapy, chemotherapy and even anti-hormonal therapy. Thus, chloroquine might very well be able to increase overall survival in small cell lung cancer by sensitizing cells resistant to chemotherapy and radiotherapy. Cures Within Reach funded lab research that suggested that chloroquine could improve the effectiveness of the cancer medication Tarceva erlotinib. The combination is now being studied in a phase II clinical trial at Massachusetts General Hospital in patients with stage IIIB and IV non–small cell lung cancer. The disruption of autophagy with chloroquine could accelerate erlotinib-induced apoptosis and overcome resistance of lung ADC cells to treatment with gefitinib or erlotinib. In cancer, authophagy is the process used by cancer cells to “self-eat” in order to survive. Specifically, if authophagy is prolonged this will become a lethal process to cancer. duing chemotheraphy, radiotheraphy, etc.) authophagy is used by cancer cells to survive. However, note that Chloroquine has other properties as well that may be very well related to anti cancer mechanism, such as zinc ionophore, and others (see below the section on mechanisms). Chloroquine for lung cancer NCI Drug Dictionary - National Cancer Institute, Using Old Drugs in New Ways - Cancer Today Malaria treated with chloroquineDrug innteraction of adderall with plaquenil Non-small cell lung cancer NSCLC is a type of malignant cancer, and 85% of metastatic NSCLC patients have a poor prognosis. C2-ceramide induces G2/M phase arrest and cytotoxicity in NSCLC cells. In this study, the autophagy-inducing effect of C2-ceramide was demonstrated, and cotreatment with the autophagy inhibitor chloroquine CQ was investigated in NSCLC H460 and H1299 cells. The results. Cancers Free Full-Text Combination Therapy of Chloroquine.. Cell death-based treatment of lung adenocarcinoma Cell.. Chloroquine potentiates the anti-cancer effect of.. Lung cancer. The combination of HCQ with erlotinib can be used safely in daily doses of 150 mg erlotinib and 1000 mg HCQ, as determined by a phase-1 study in 27 patients with advanced non-small cell lung cancer NSCLC. Of the 19 patients who remained in the study, one had a partial response and four had stable disease as best response. Indeed, current clinical trials are trying to use chloroquine or hydroxychloroquine, alone or in combination with other drugs to inhibit autophagy during breast cancer therapy since chemotherapy and radiation, regimens that are used to treat breast cancer, are known to induce autophagy in cancer cells. Chloroquine CQ is a widely used antimalarial drug with emerging potential in anticancer therapies due to its apparent inhibitory effects on CXCR4 chemokine receptor, autophagy, and cholesterol metabolism. This study reports on polymeric CQ pCQ as a macromolecular drug with antimetastatic activity.